赛诺菲(中国)投资有限公司上海分公司
赛诺菲集团赛诺菲集团是一家全球领先的多元化医药健康企业，专注于患者需求，传播健康。Ø 全球100,000余名员工，业务遍及100个国家 Ø 新兴市场实力均衡，表现强劲，位列第一 Ø 多元领域，覆盖处方药、健康药业产品、疫苗和动物保健品Ø 疫苗领域的领导者 Ø 领先动物保健市场 Ø 2011年集团净销售额达334亿欧元
赛诺菲在中国赛诺菲是首批在中国开设办事处的跨国制药集团，也是国内增长最快的医药健康企业之一。目前，赛诺菲在中国200多个城市拥有6500余名员工。 传承悠久历史、持续开拓进取赛诺菲一直以来秉承对中国的承诺。1982年，赛诺菲成为首批在中国开设办事处的跨国制药企业之一。今天，赛诺菲已跻身中国医药健康市场的领军企业。赛诺菲的中国总部位于上海，并在北京、天津、沈阳、济南、上海、杭州、南京、武汉、成都、广州和乌鲁木齐共设11家区域办公室。 独特的医药健康产品系列、满足中国公共卫生需求从预防到治疗，赛诺菲全方位满足中国的公共健康需求。集团的疫苗事业部赛诺菲巴斯德是中国领先的疫苗企业。赛诺菲在心血管/血栓、糖尿病、肿瘤、内科和中枢神经系统等关键的治疗领域拥有领先产品。2010年，杭州赛诺菲民生健康药业有限公司的成立标志着赛诺菲进入中国的非处方药市场。2011年2月，赛诺菲完成了对BMP太阳石的收购，籍此拥有国内最大的小儿感冒咳嗽品牌“好娃娃®”。 大幅投资工业建设、满足中国市场需求赛诺菲目前在中国拥有六家生产基地，包括北京制药工厂、杭州制药工厂、杭州赛诺菲民生健康药业工厂、南昌梅里亚动物保健工厂、深圳赛诺菲巴斯德疫苗工厂、以及唐山健康药业工厂。 完善的研发架构、双赢的研发合作模式在中国，赛诺菲具有从药物靶点发现到后期临床研究的整体研发实力。集团在上海设有中国研发中心和亚太研发中心，并在北京和成都分别设有研发机构。自2008年以来，赛诺菲与中国权威科研机构开展了10多项战略合作，在癌症、干细胞、糖尿病和老年疾病等前沿研究领域探索创新药物 如需了解更多信息，请访问www.sanofi.cn
-----------------------------------------------------------------------------------------
Sanofi in China Sanofi is one of the first foreign pharmaceutical companies to open offices in China. It is also one of the fastest growing healthcare companies in China, with 6,500 people in more than 200 cities across China. A long heritage and expanding footprintIn 1982, Sanofi became one of the first foreign pharmaceutical companies to open offices in China. Today, Sanofi has one of the largest workforce in the Chinese healthcare industry. Sanofi’s China headquarters are in Shanghai, supported by 11 regional offices in Beijing, Tianjin, Shenyang, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Jinan and Urumqi. Uniquely positioned to address public health needs in China Ø Disease Prevention – Sanofi Pasteur, the vaccines division of Sanofi, is a worldwide leader of vaccines. Sanofi Pasteur has a broad portfolio to meet pediatric and adult immunization requirements in China, including influenza (Vaxigrip), pediatric diseases (IPV), Rabies (Verorab). SP expects to launch Pentaxim, the first pediatric 5-in-1 vaccine in China, in 2011.Ø Consumer Healthcare – In October 2010, Sanofi entered the consumer healthcare market in China, with the establishment of Hangzhou Sanofi Minsheng Consumer Healthcare Co., Ltd, which focuses on Vitamins and Mineral Supplements (VMS). Sanofi has a majority equity stake in this joint venture with Minsheng Pharmaceutical Group. In Feb 2011, Sanofi successfully completed the acquisition of BMP Sunstone, which allows Sanofi to own China\'s most recognized children cough&cold brand: “Hao Wa Wa” (GoodBaby). These collaborations provide Sanofi a strong position in both Vitamins & Minerals Supplements and Cough&Cold, the two largest categories of China OTC market. Ø Key Therapeutic Areas– China has over 92 million diabetes patients1. With Lantus and Amaryl, Sanofi is the fastest growing company in diabetes2.– Plavix, our anti-platelet drug for PCI / ACS / Stroke is the largest Rx product in China2.– China has 200 million hypertension patients3, and ARB is the fastest growing class. Aprovel is the
1 ARB drug by volume2.– Approximately 10% of the Chinese population is affected by the fatty liver disease4. Essentiale is the
1 oral hepatic protector2. – Cancer remains the number one cause of death in China. Eloxatin and Taxotere address a broad range of cancer types. New industrial investment to better meet the growing demand of the Chinese marketSanofi currently has three manufacturing facilities in Beijing, Hangzhou, and Shenzhen. In addition, the company is building three new facilities, all scheduled to begin commercial production in 2012. This includes:Ø Expanding the current manufacturing facility in Beijing to build pre-filled injection production lines for Lantus® (Insulin Glargine) SoloSTAR®Ø Building a new manufacturing site in Binjiang New Development Zone in Hangzhou to replace the current facility in downtown HangzhouØ Building a hi-tech manufacturing facility in Shenzhen to produce Vaxigrip® for the prevention of seasonal influenza and to contribute to pandemic readiness in China Integrated and Collaborative R&D Sanofi is engaged in integrated R&D in China from drug target identification to late stage clinical studies. Its China R&D Center and Asia Pacific R&D Center are based in Shanghai, supported by branches in Beijing and Chengdu. Since 2008, Sanofi has established over ten strategic collaborations on the discovery front with top scientific institutions in China in cutting-edge research in cancer, stem cell, diabetes and age-related diseases. For more information, visit www.sanofi.cn or www.sanofi.com
1) Diabetes: Wenying Yang et al, NEJM, vol 36, 1090-1101, March 25, 2010; ACS/Stroke estimate: Mc Kinsey analysis2) IMS MAT Nov 2010 in Value (Insulin market: A10C, ARB Market: C09C+D looking at ARB brand families, Essentiale market: A05Borals, Onco TA: L class ANTINEOPLAST+IMMUNOMODUL) 3) MOH 2007 yearly report on Cardiovascular Diseases in China4) J Hepatol, 2009 Jan; 50(1): 204-10
